Literature DB >> 26854155

Brown Tumors Due to Primary Hyperparathyroidism in a Patient with Parathyroid Carcinoma Mimicking Skeletal Metastases on (18)F-FDG PET/CT.

Kim Francis Andersen1, Elisabeth Albrecht-Beste2.   

Abstract

Parathyroid carcinoma only represents <1% of all cases of primary hyperparathyroidism (PHPT). Even rare, chronic PHPT may lead to excessive osteoclast activity, and the increased resorption leads to destruction of cortical bone and formation of fibrous cysts with deposits of hemosiderin-so-called brown tumors. These benign, osteolytic lesions may demonstrate FDG-avidity on (18)F-FDG PET/CT, and as such are misinterpreted as skeletal metastases. Regression of the lesions may occur following successful treatment. We present a case demonstrating the diagnostic work-up and follow-up of a patient with PHPT due to parathyroid carcinoma and with presence of brown tumors on (18)F-FDG PET/CT, visualizing the possible role of this imaging modality in the evaluation of treatment response in these patients.

Entities:  

Keywords:  FDG PET; brown tumors; parathyroid carcinoma; primary hyperparathyroidism

Year:  2015        PMID: 26854155      PMCID: PMC4665606          DOI: 10.3390/diagnostics5030290

Source DB:  PubMed          Journal:  Diagnostics (Basel)        ISSN: 2075-4418


(a) Initial scan—left and middle: CT (bone window) and fused 18F-FDG PET/CT, transaxial view; right: 18F-FDG PET, maximal intensity projection. A 53-year old man with persistent bone pain localized to the knees, fatigue, and memory loss. Diagnostic work-up came out with strongly elevated plasma levels of parathyroid hormone (PTH, 180 pmol/L (normal range 1.18–8.43 pmol/L)) and ionized calcium (2.27 mmol/L (normal range 1.18–1.32 mmol/L)). Medical treatment with calcimimetics was initialized. The patient was referred to a fluorine-18 fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (18F-FDG PET/CT), which demonstrated multiple FDG-avid osteolytic and destructive lesions located to the peripheral and axial skeleton, some of the lesions with an extra-skeletal compartment. The lesions were suspected of being skeletal metastases. The white arrows point at a FDG-avid costal osteolytic lesion on the right side with maximal standardized uptake value (SUVmax) of 7.2; (b) Initial scan—CT (mediastinal window) and fused 18F-FDG PET/CT, coronal view. In addition, a 2.5 cm paratracheal lesion with central calcifications located inferior to the left lobe of the thyroid gland was visualized on CT. The lesion demonstrated no pathological FDG uptake (SUVmax 2.8) and was concluded as being a parathyroid tumor (white arrows). Due to suspiciousness of primary hyperparathyroidism (PHPT), surgery was performed in terms of left-sided hemithyroidectomy and en bloc resection of the parathyroid tumor including regional lymph nodes. A spontaneous drop in PTH plasma levels of approximately 85% was seen 5 min after removal of the parathyroid tumor. Histopathology demonstrated parathyroid carcinoma with infiltrative growth pattern and invasion of vessels. The surgical margins were negative, and there were no lymph node metastases in the resected tissue; (c) Follow-up scan—left and middle: CT (bone window) and fused 18F-FDG PET/CT, transaxial view; right: 18F-FDG PET, maximal intensity projection. As staging of the disease was essential in terms of choice of treatment, a core needle biopsy from a FDG-avid osteolytic lesion in the left ilium seen on the pre-operative 18F-FDG PET/CT scan was performed. Histopathology was inconclusive due to lack of representative tissue. A follow-up 18F-FDG PET/CT scan was performed 3 months after surgery, and the previously seen osteolytic lesions were sclerotized with normal or only slightly increased FDG uptake. SUVmax of the previously mentioned costal lesion on the right side was now 2.5 (white arrows). In addition, both the patient’s symptoms as well as plasma levels of PTH and ionized calcium were normalized on further medical treatment. The lesions initially seen on 18F-FDG PET/CT were concluded as being benign brown tumors due to PHPT in this patient with parathyroid carcinoma. This case illustrates two clinical dilemmas: (1) A patient with parathyroid carcinoma, which was not visible on 18F-FDG PET due to lack of pathological FDG uptake in the tumor detected on CT; (2) The presence of multiple benign bone lesions with high FDG-avidity, which mimicked metastatic disease and as such could be misinterpreted. Parathyroid carcinoma is rare, representing <1% of all cases of PHPT [1]. Even though 18F-FDG PET/CT can offer information regarding lesion metabolism and potential loco-regional and/or distant spread of malignant disease [2], it probably has no place in the diagnostic work-up in a group of unselected patients with PHPT [3]. Despite the nomenclature, brown tumors are not true neoplasms, but rare, benign osteolytic lesions, which arise in the setting of excessive osteoclast activity in patients with hyperparathyroidism. The increased resorption leads to destruction of cortical bone and formation of fibrous cysts. Microscopically, hemosiderin deposition in the cysts gives a characteristic brown coloration and osteoclast-like giant cells may be present. The increased FDG uptake, which can be seen in these lesions (possibly due to the presence of osteoclast-like giant cells and macrophage glucose metabolism [4]), may mimic skeletal metastasis on 18F-FDG PET/CT. However, regression of the lesions has been reported after successful parathyroidectomy [5,6,7], supported by the findings in our case report. This indicates a possible role of 18F-FDG PET/CT in the evaluation of treatment response in these patients.
  7 in total

1.  ¹⁸F-FDG PET findings of a parathyroid cancer with cortical skeletal demineralization.

Authors:  Hye-kyung Shim; Bom Sahn Kim
Journal:  Clin Nucl Med       Date:  2012-03       Impact factor: 7.794

2.  Augmentations of glucose uptake and glucose transporter-1 in macrophages following thermal injury and sepsis in mice.

Authors:  R L Gamelli; H Liu; L K He; C A Hofmann
Journal:  J Leukoc Biol       Date:  1996-05       Impact factor: 4.962

3.  Increased 18F-fluorodeoxyglucose uptake in a brown tumor in a patient with primary hyperparathyroidism.

Authors:  Kazuhiro Kuwahara; Shoichiro Izawa; Hiroyuki Murabe; Norihiko Murakami; Toshihiko Yokota; Yoji Wani; Kenji Notohara; Choutatsu Tsukayama; Takayoshi Ishimori; Yuji Watanabe
Journal:  J Clin Endocrinol Metab       Date:  2007-07       Impact factor: 5.958

4.  Multiple skeletal lesions on FDG PET in severe primary hyperparathyroidism.

Authors:  M N Kerstens; R de Vries; J T M Plukker; R H J A Slart; R P F Dullaart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-07-23       Impact factor: 9.236

Review 5.  The role of radionuclide imaging in the surgical management of primary hyperparathyroidism.

Authors:  Elif Hindié; Paolo Zanotti-Fregonara; Antoine Tabarin; Domenico Rubello; Isabelle Morelec; Tristan Wagner; Jean-François Henry; David Taïeb
Journal:  J Nucl Med       Date:  2015-04-09       Impact factor: 10.057

6.  Prognostic factors and staging systems in parathyroid cancer: a multicenter cohort study.

Authors:  Jesús Villar-del-Moral; Antonio Jiménez-García; Pilar Salvador-Egea; Juan M Martos-Martínez; José M Nuño-Vázquez-Garza; Mario Serradilla-Martín; Angel Gómez-Palacios; Pablo Moreno-Llorente; Joaquín Ortega-Serrano; Aitor de la Quintana-Basarrate
Journal:  Surgery       Date:  2014-10-17       Impact factor: 3.982

7.  FDG-PET/CT and parathyroid carcinoma: Review of literature and illustrative case series.

Authors:  Laura Evangelista; Nadia Sorgato; Francesca Torresan; Isabella Merante Boschin; Gianmaria Pennelli; Giorgio Saladini; Andrea Piotto; Domenico Rubello; Maria Rosa Pelizzo
Journal:  World J Clin Oncol       Date:  2011-10-10
  7 in total
  4 in total

1.  A patient with a history of breast cancer and multiple bone lesions: a case report.

Authors:  Marie-Angela Schnyder; Paul Stolzmann; Gerhard Frank Huber; Christoph Schmid
Journal:  J Med Case Rep       Date:  2017-05-06

Review 2.  MANAGEMENT OF ENDOCRINE DISEASE: Unmet therapeutic, educational and scientific needs in parathyroid disorders.

Authors:  Jens Bollerslev; Camilla Schalin-Jäntti; Lars Rejnmark; Heide Siggelkow; Hans Morreau; Rajesh Thakker; Antonio Sitges-Serra; Filomena Cetani; Claudio Marcocci
Journal:  Eur J Endocrinol       Date:  2019-06-01       Impact factor: 6.664

3.  BROWN TUMORS SECONDARY TO PARATHYROID CARCINOMA MASQUERADING AS SKELETAL METASTASES ON 18F-FDG PET/CT: A CASE REPORT.

Authors:  Yumiko Tsushima; Simeng Sun; Michael A Via
Journal:  AACE Clin Case Rep       Date:  2019-03-13

4.  Subchondral Bone Restoration of Supra-acetabular Brown Tumor Secondary to Parathyroid Carcinoma: A Case Report.

Authors:  Yong-Jin Park; Taek-Rim Yoon; Kyung-Soon Park; Jee-Wook Ko
Journal:  Hip Pelvis       Date:  2018-06-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.